Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2007.12.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liposome-encapsulated aprotinin biodistribution in mice: Side-by-side comparison with free drug formulation.
Biochem Biophys Res Commun
November 2024
ChemRar RDI, LLC, 40 Bolshoy Blvd, 121205, Moscow, Russia.
Injuries of the respiratory system caused by viral infections (e.g., by influenza virus, respiratory syncytial virus, metapneumovirus, or coronavirus) can lead to long-term complications or even life-threatening conditions.
View Article and Find Full Text PDFAprotinin (I): Understanding the Role of Host Proteases in COVID-19 and the Importance of Pharmacologically Regulating Their Function.
Int J Mol Sci
July 2024
Department of Medical Sciences, School of Medicine at Ciudad Real, University of Castilla-La Mancha, 13971 Ciudad Real, Spain.
Proteases are produced and released in the mucosal cells of the respiratory tract and have important physiological functions, for example, maintaining airway humidification to allow proper gas exchange. The infectious mechanism of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), takes advantage of host proteases in two ways: to change the spatial conformation of the spike (S) protein via endoproteolysis (e.g.
View Article and Find Full Text PDFAprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.
Int J Mol Sci
June 2024
Department of Medical Sciences, School of Medicine at Ciudad Real, University of Castilla-La Mancha, 13971 Ciudad Real, Spain.
Aprotinin is a broad-spectrum inhibitor of human proteases that has been approved for the treatment of bleeding in single coronary artery bypass surgery because of its potent antifibrinolytic actions. Following the outbreak of the COVID-19 pandemic, there was an urgent need to find new antiviral drugs. Aprotinin is a good candidate for therapeutic repositioning as a broad-spectrum antiviral drug and for treating the symptomatic processes that characterise viral respiratory diseases, including COVID-19.
View Article and Find Full Text PDFPharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis.
Cochrane Database Syst Rev
January 2024
Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.
Article Synopsis
- Hip and knee replacement surgeries can significantly improve quality of life but carry risks of bleeding, with many patients suffering from anemia before and after the surgery, leading to high rates of blood transfusions.
- The study aims to evaluate the effectiveness of various pharmacological interventions in minimizing blood loss during these surgeries and to determine the best timing, dosage, and method of administration for these treatments.
- A comprehensive search of several medical databases was conducted to gather randomized controlled trials focused on elective hip and knee surgeries, excluding emergency cases and studies that did not follow proper registration protocols.
Ulinastatin in combination with aprotinin improves systemic inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass.
Am J Transl Res
November 2023
Department of Cardiovascular Medicine, The First Hospital of Yulin Yulin 718000, Shaanxi, China.
Objective: To investigate the impact of ulinastatin combined with protease inhibitors on serum inflammatory factors in patients undergoing cardiac surgery with cardiopulmonary bypass.
Methods: A retrospective analysis was conducted on 86 patients who underwent cardiac surgery with cardiopulmonary bypass at Xi'an Gaoxin Hospital from May 2019 to June 2021. Based on the administration of drugs by a micro-infusion pump after anesthesia induction and before skin incision, the patients were divided into an observation group (receiving ulinastatin at a dose of 12,000 U/kg and protease inhibitors at a dose of 4 million units) with 46 cases and a control group (receiving protease inhibitors at a dose of 2 million units) with 40 cases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!